How India Exports Calcium to the World

In the United States, calcium-based pharmaceutical products are subject to regulation by the Food and Drug Administration (FDA). The FDA's Orange Book lists approved drug products, including those containing calcium. As of March 2026, there are multiple approved Abbreviated New Drug Applications (ANDAs) for calcium supplements, indicating a competitive market with several generic options available. Recent approvals include a calcium carbonate tablet by a major Indian exporter in January 2026.

The regulatory pathway for calcium products involves demonstrating bioequivalence to a reference listed drug (RLD). Given the substantial number of active Indian exporters (996) supplying calcium to the U.S., compliance with FDA regulations, including Good Manufacturing Practices (GMP) and accurate labeling, is imperative to maintain market access.

In the European Union (EU) and the United Kingdom (UK), calcium-containing medicinal products require marketing authorization from the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. These agencies mandate adherence to EU Good Manufacturing Practice (GMP) guidelines, ensuring product quality and safety. Notably, in December 2025, the EMA updated its guidelines on the quality requirements for calcium supplements, emphasizing stricter impurity controls.

Calcium is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The 24th edition, published in September 2025, lists calcium under the vitamins and minerals section. This inclusion highlights the necessity of calcium in addressing public health needs worldwide. Manufacturers are expected to comply with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure product quality and consistency.

In India, calcium supplements are classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for sale. The National Pharmaceutical Pricing Authority (NPPA) sets ceiling prices for essential medicines; however, as of March 2026, calcium supplements are not subject to price control under the Drug Price Control Order (DPCO). For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with international standards and regulations.

Calcium supplements are generally off-patent, allowing for robust generic competition. This competitive landscape is reflected in the significant number of active Indian exporters (996) and the average Free on Board (FOB) unit price of $7.51, indicating a mature market with price sensitivity.

In May 2025, the NPPA conducted a review of calcium supplement prices, concluding that no immediate price controls were necessary due to sufficient market competition. In August 2025, the CDSCO issued a directive requiring enhanced labeling for calcium supplements, including clearer dosage instructions and potential side effects, to improve consumer safety. In October 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of calcium, which may influence global demand and regulatory focus. In December 2025, the EMA revised its guidelines on the quality requirements for calcium supplements, emphasizing stricter impurity controls, impacting exporters targeting the EU market. In February 2026, the FDA issued an import alert for a specific batch of calcium supplements from an Indian exporter due to quality concerns, highlighting the importance of stringent quality control measures.

These developments underscore the dynamic regulatory environment for calcium supplements, necessitating continuous monitoring and compliance by exporters to maintain market access and competitiveness.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on imports for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of these essential components are sourced from China, creating a significant vulnerability in the supply chain. This dependency has been highlighted during recent geopolitical tensions and the COVID-19 pandemic, which led to supply chain disruptions and price volatility.

In response, the Indian government has initiated the Production Linked Incentive (PLI) scheme to bolster domestic production of APIs and KSMs. Notably, in October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, aiming to reduce import dependence by half. However, challenges persist, including cost competition from Chinese manufacturers, who have reportedly slashed prices of certain APIs by up to 50% in 2025, potentially undermining India's self-sufficiency efforts.

The export data for calcium from India reveals a high supplier concentration, with the top five exporters accounting for 74.6% of the total export value. INTAS PHARMACEUTICALS LIMITED leads with a 28.1% share, followed by MYLAN LABORATORIES LIMITED (17.7%), PIRAMAL PHARMA LIMITED (16.3%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (6.4%), and BIOCON PHARMA LIMITED (6.1%). This concentration poses a single-source risk, as disruptions affecting any of these key players could significantly impact the supply chain.

The PLI scheme aims to mitigate such risks by encouraging diversification and enhancing domestic production capabilities. While progress has been made, the full impact of these initiatives on reducing supplier concentration remains to be seen.

Recent geopolitical events have severely disrupted global shipping routes. In March 2026, the Strait of Hormuz was effectively closed due to escalating conflicts, leading to a near halt in maritime traffic and affecting approximately 20% of the world's daily oil supply. This disruption has had cascading effects on global supply chains, including the pharmaceutical sector, by increasing shipping costs and causing delays.

Additionally, tensions in the Red Sea and the Bab al-Mandab Strait have further complicated shipping routes, forcing companies to reroute vessels around Africa's Cape of Good Hope, adding weeks to transit times and escalating costs. (lemonde.fr) These disruptions underscore the vulnerability of the pharmaceutical supply chain to geopolitical events, emphasizing the need for robust risk mitigation strategies.

• Diversify Supplier Base: Encourage the development of alternative suppliers, both domestically and internationally, to reduce reliance on a concentrated group of exporters.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme and similar initiatives to boost local manufacturing of APIs and KSMs, thereby reducing dependency on imports.

• Strengthen Supply Chain Resilience: Develop contingency plans, including alternative shipping routes and logistics strategies, to mitigate the impact of geopolitical disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to continuously assess geopolitical risks and their potential impact on the supply chain, enabling proactive responses.

• Invest in Infrastructure: Improve domestic infrastructure to support efficient production and distribution of pharmaceutical products, reducing vulnerabilities associated with external dependencies.

RISK_LEVEL: HIGH